Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer

Breast Cancer Research and Treatment

Volumn 100, Issue 1, 2006, Pages 33-47

  Shi, Yue Y ^a   Small, George W ^a   Orlowski, Robert Z ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Bortezomib; MKP 1; p38 MAPK; Proteasome

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CELL CYCLE PROTEIN; DUAL SPECIFICITY PHOSPHATASE 1; IMMEDIATE EARLY PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL LINE; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BORONIC ACIDS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; FEMALE; HUMANS; IMMEDIATE-EARLY PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEIN PHOSPHATASE; PROTEASE INHIBITORS; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES;

EID: 34249062137     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-006-9232-x     Document Type: Article

References (40)

1. Ciechanover A (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6:79-87
2. Orlowski M, Wilk S (2000) Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 383:1-16
3. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325 (Pubitemid 38031815)
4. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639 (Pubitemid 46224241)
5. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427 (Pubitemid 35334752)
6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617 (Pubitemid 36741588)
7. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498 (Pubitemid 41007864)
8. Orlowski RZ (2005) The ubiquitin proteasome pathway from bench to bedside. Hematology (Am Soc Hematol Educ Program) 220-225
9. Dees EC, Orlowski RZ (2006) Targeting the ubiquitin-proteasome pathway in breast cancer. Future Oncol 2:121-135
10. Meriin AB, Gabai VL, Yaglom J, Shifrin VI, Sherman MY (1998) Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 273:6373-6379 (Pubitemid 28144729)
11. Robertson JD, Datta K, Biswal SS, Kehrer JP (1999) Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem J 344 Pt 2:477-485 (Pubitemid 30011605)
12. Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC (2004) p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23:8766-8776 (Pubitemid 39593291)
13. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC (2003) Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63:6174-6177 (Pubitemid 37255160)
14. Orlowski RZ, Small GW, Shi YY (2002) Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 277:27864-27871 (Pubitemid 34966732)
15. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ (2004) Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66:1478-1490 (Pubitemid 39564774)
16. Li J, Gorospe M, Hutter D, Barnes J, Keyse SM, Liu Y (2001) Transcriptional induction of MKP-1 in response to stress is associated with histone H3 phosphorylation-acetylation. Mol Cell Biol 21:8213-8224 (Pubitemid 33051810)
17. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58:4342-4348 (Pubitemid 28450035)
18. Clark R, Stampfer MR, Milley R, O'Rourke E, Walen KH, Kriegler M, Kopplin J, McCormick F (1988) Transformation of human mammary epithelial cells by oncogenic retroviruses. Cancer Res 48:4689-4694
19. Lasfargues EY, Coutinho WG, Redfield ES (1978) Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 61:967-978 (Pubitemid 9042085)
20. Cailleau R, Young R, Olive M, Reeves WJ Jr (1974) Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53:661-674
21. Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ (2003) Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 307:861-869 (Pubitemid 37494202)
22. Small GW, Chou TY, Dang CV, Orlowski RZ (2002) Evidence for involvement of calpain in c-Myc proteolysis in vivo. Arch Biochem Biophys 400:151-161 (Pubitemid 34852395)
23. Young PR (2000) Specific inhibitors of p38 MAPK kinase. In: JS Gutkind (ed) Signaling networks, cell cycle control. Humana Press, Totawa NJ, pp 483-500
24. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE (1996) Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/ p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279:1453-1461 (Pubitemid 27166795)
25. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746
26. Yu R, Mandlekar S, Lei W, Fahl WE, Tan TH, Kong AT (2000) p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem 275:2322-2327 (Pubitemid 30081988)
27. Huang M, Wang Y, Collins MA, Gu JJ, Mitchell BS, Graves LM (2002) Inhibition of nucleoside transport by p38 MAP kinase inhibitors. J Biol Chem 277:28364-28367 (Pubitemid 41079256)
28. Barancik M, Bohacova V, Kvackajova J, Hudecova S, Krizanova O, Breier A (2001) SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 14:29-36 (Pubitemid 32655412)
29. Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, Chen Q, McLeish KR, Klein JB (2003) Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem 278:27828-27835 (Pubitemid 36899975)
30. Lali FV, Hunt AE, Turner SJ, Foxwell BM (2000) The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 275:7395-7402 (Pubitemid 30146294)
31. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS (2004) Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100:499-506 (Pubitemid 38124766)
32. Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME (2004) Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 24:1473-14780
33. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD (2004) Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64:1757-1764 (Pubitemid 38428699)
34. Wang HY, Cheng Z, Malbon CC (2003) Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 191:229-237 (Pubitemid 36255609)
35. Wu W, Pew T, Zou M, Pang D, Conzen SD (2005) Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280:4117-4124 (Pubitemid 40288576)
36. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058-3065
37. Zhang CC, Shapiro DJ (2000) Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem 275:479-486 (Pubitemid 30039009)
38. Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J, Chen G (2003) p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem 278:74831-74839
39. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC (2003) Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22:8386-8393 (Pubitemid 37523890)
40. David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S (2005) The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 106:4322-4329 (Pubitemid 41775943)